- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
AstraZeneca wins over UK doctors
10 September 2009
Medical representatives from AstraZeneca came out top with UK doctors in a survey conducted by Doctors.net.uk.
More than 600 primary and secondary care doctors were asked to vote for representatives they valued in terms of communication skills, technical skills as well as for those they most enjoyed meeting. AstraZeneca was the most highly rated but a number of smaller firms also did well compared with the bigger companies, including Takeda, Ferring and Eisai.
The complete Top Ten are as follows: Eli Lilly, Pfizer, GlaxoSmithKline, Janssen Cilag, Sanofi-aventis, Novartis, Boehringer Ingelheim, Bristol-Myers Squibb and Merck Sharpe & Dohme.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
